elisabetta setola

Sarcoma Oncologist at IEO- European Institute of Oncology, MD, PhD

[Dario Trapani @darioT_]

So exciting to see this new initiative from @myESMO !
For all academic reserchers, cooperative groups, and re your ideas that are relevant to patients & #cancer care, everywhere, this opportunity is UNMISSABLE!!

[Professor Georgina Long AO (Bluesky @gvlongphdmd) @ProfGLongMIA]

Day 2 at #ASCO2026! A strong showing from @MelanomaAus. Here are our poster highlights with my great colleagues Ines da Silva & Alex van Akkooi.  

My NeoIRENIE trial in progress - a trial designed to rapidly answer a critical question for the field can we use our biomarker that predicts who is in the ‘third space’ (those that dies for melanoma) and give them our best drugs upfront early-on in their cancer journey.  A true MIA multidisciplinary trial, and now open, expanding across Australia and internationally.

MSLT-3  - Alex van Akkooi's MIA-led surgical trial opening globally.  Is less surgery OK for stage III neoadjuvant melanoma treated patients?

Ines Da Silva’s leading work on the dynamic tool predicting recurrence on and off adjuvant immunotherapy in early-stage melanoma. She also presented on PD-1 vs Ipi+Nivo in uveal melanoma which builds towards a melanoma oral on tomorrow.

I was delighted to also present the updated brenetafusp (ImmTAC) data, a molecule that bridges T cells (immune cell) directly to tumour cells and showing activity in the 'third space’. 

The #science is moving!

#melanoma @ASCO @Sydney_Uni @syd_health @Science_Academy @AAHMS_health @FulbrightAUS @ausoftheyear

[IEO @IEOufficiale]

🚀 Coming soon at #ASCO26!

La Dott. Sanfilippo direttore unita sarcomi dello IEO, guiderà il Clinical Science Symposium dedicato agli Antibody-Drug Conjugates nei sarcomi, una delle strategie terapeutiche più promettenti dell’oncologia moderna.

Nuovi target, nuove tecnologie

[Moffitt Cancer Center @MoffittNews]

During #ASCO26, Nikhil Khushalani, MD, shares research exploring combination therapy approaches in metastatic uveal melanoma and how biomarker research may help inform future treatment strategies. #MoffittASCO26

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[IEO @IEOufficiale]

🚨 #ASCO26 SARC041 delivers the first positive phase III trial in DDLPS.
Abemaciclib significantly improved PFS vs placebo (9.7 vs 1.5 months; HR 0.38).
Cross-trial comparisons remain challenging, especially with studies using active comparators such as doxorubicin.
#Sarcoma #IEO

[IEO @IEOufficiale]

🚨 Happening now at #ASCO26!

Dr. Andrew Wagner presents the Phase III PEAK study in advanced #GIST:

✅ ORR 45.6% vs 25.8%
✅ mPFS 16.5 vs 9.2 months
✅ 50% reduction in risk of progression or death (HR 0.50)

Potential new standard in 2L GIST. #Sarcoma #Oncology#GIST

[IEO @IEOufficiale]

🚨 #ASCO26

Velzatinib shows promising efficacy across KIT mutation profiles in advanced #GIST, with a favorable safety profile.

IEO is enrolling the randomized trial of velzatinib vs sunitinib in second-line GIST.

#Sarcoma #ClinicalTrials #Oncology

[IEO @IEOufficiale]

🔥 Is varegacestat setting a new benchmark in desmoid tumors?

Phase III #RINGSIDE

Compared with the pivotal DeFi trial of nirogacestat, cross-trial comparisons suggest potentially deeper efficacy, while dose modifications remain frequent.

#DesmoidTumor #Sarcoma #ASCO26

[IEO @IEOufficiale]

🎯 Big day for sarcoma at #ASCO2026!
Liposarcoma reaches the Plenary Session. The IEO Sarcoma Unit will be there to follow the data and share key takeaways. Stay tuned! 🚀 #Sarcoma #Liposarcoma

[IEO @IEOufficiale]

🚨 #ASCO2026 Plenary Session is about to begin!

IEO is ready to follow the latest practice-changing oncology data and discuss their impact on patient care.

Stay tuned! 👀 #ASCO26 #Oncology #CancerResearch #Sarcoma #IEOoncology

[IEO @IEOufficiale]

🔬 Ahead of #ASCO2026, the SARC Semiannual Meeting in Chicago brings together the sarcoma community to discuss new therapeutic strategies, precision oncology and innovative clinical trials.

🌍 Global collaboration remains key to advancing care for patients with sarcoma.

[IEO @IEOufficiale]

🚀 Big news in #GIST!

FDA accepts the NDA for bezuclastinib + sunitinib after positive Phase III PEAK results.

👀 The IEO Sarcoma Unit will be following the oral presentation of the full PEAK data at #ASCO26 on May 30, 3:00–6:00 PM CT.

#Sarcoma #IEO

[Inhibrx Biosciences, Inc. @inhibrx]

Today at the #CTOS2025 Annual Meeting, Dr. Robin L. Jones presented topline results from ChonDRAgon, the registrational phase 2 study evaluating ozekibart (#INBRX109) in chondrosarcoma, part of the Chondrosarcoma: Sarcoma of the Year session.

[SARC @SARCtrials]

We at SARC are deeply saddened by the loss of Dr. Brian Van Tine.

His leadership, mentorship, and dedication shaped the sarcoma research community.

We extend our condolences to his family, friends, colleagues, and all who were touched by his work.

[Guilherme Nader Marta @GuiNaderMarta]

TILs are prognostic in early-stage TNBC, though visual scoring still shows variability

In the randomized TBCRC-030 trial, visual & AI-based TIL assessment predicted response to NACT, though AI did not outperform visual review

@DFCI_BreastOnc @OncoAlert

https://t.co/HvWx2i0ag7

[Inhibrx Biosciences, Inc. @inhibrx]

Inhibrx is excited to share the results of ChonDRAgon, our registrational trial of ozekibart (#INBRX109) in chondrosarcoma, as well as updates on colorectal cancer and Ewing sarcoma from our ongoing Phase 1/2 #ClinicalTrial.

Read the full press release: https://t.co/PMaomBayR6

[Lorenzo D'Ambrosio @DAmbrosio_MD]

📢The @ItaSarcomaGroup consensus paper on extended molecular profiling 🧬in mesenchymal tumors is out‼️
Huge thanks to everyone who contributed to this collaborative effort!
@SilviaStacchia @merlini_ale
@sbamarta @apdeitos @MartinaRab95
https://t.co/09v5HAKr56

[G Curigliano MD PhD @curijoey]

🇮🇹 The ROME trial marks a milestone for Italy’s precision oncology platform: 6 years of dedication, 40 centers, 1,794 patients sequenced. A national effort to bring genomics to the heart of cancer care. @myESMO @IEOufficiale @LaStatale

[Carmine Valenza @ValenzaCarmine]

Happy to share our perspective on the future of PROTAC ER degraders for #patients with metastatic breast cancer in the @ASCO Daily News

- with @curijoey

https://t.co/pH4ccitbgh

@LaStatale @IEOufficiale